Viking Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 4 | -$0.26 | -$0.26 | -$0.26 |
| Q2 2024 | 4 | -$0.24 | -$0.24 | -$0.24 |
| Q3 2024 | 11 | -$0.33 | -$0.24 | -$0.28 |
| Q1 2025 | 3 | -$0.37 | -$0.28 | -$0.31 |
| Q2 2025 | 2 | -$0.35 | -$0.35 | -$0.35 |
| Q3 2025 | 2 | -$0.40 | -$0.40 | -$0.40 |
| Q4 2025 | 2 | -$0.44 | -$0.44 | -$0.44 |
| Q1 2026 | 1 | -$0.30 | -$0.30 | -$0.30 |
| Q2 2026 | 1 | -$0.30 | -$0.30 | -$0.30 |
| Q3 2026 | 1 | -$0.30 | -$0.30 | -$0.30 |
| Q4 2026 | 1 | -$0.30 | -$0.30 | -$0.30 |
| Q1 2027 | 1 | -$0.35 | -$0.35 | -$0.35 |
| Q2 2027 | 1 | -$0.42 | -$0.42 | -$0.42 |
| Q3 2027 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q4 2027 | 1 | -$0.48 | -$0.48 | -$0.48 |
Viking Therapeutics, Inc. Earnings Date And Information
Viking Therapeutics, Inc. last posted its earnings results on Wednesday, October 23rd, 2024. The company reported $-0.22 earnings per share for the quarter, topping analysts' consensus estimates of $-0.24 by $0.02. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Viking Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-0.91 diluted earnings per share) and currently has a price-to-earnings ratio of -71.34. Viking Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based on prior year's report dates.
Viking Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/23/2024 | Q3 2024 | -$0.24 | -$0.22 | 0.02 | $0 | $0 |
| 07/24/2024 | Q2 2024 | -$0.26 | -$0.20 | 0.06 | $0 | $0 |
| 04/24/2024 | Q1 2024 | -$0.26 | $0 | |||
| 02/07/2024 | Q4 2023 | -$0.25 | -$0.25 | 0 | $436,000 | |
| 10/25/2023 | Q3 2023 | -$0.22 | -$0.23 | -0.01 | $0 | |
| 07/26/2023 | Q2 2023 | -$0.21 | -$0.19 | 0.02 | $0 | |
| 04/26/2023 | Q1 2023 | -$0.24 | -$0.24 | 0 | $0 | |
| 02/09/2023 | Q4 2022 | -$0.25 | $0 | |||
| 10/26/2022 | Q3 2022 | -$0.23 | -$0.20 | 0.03 | $0 | |
| 07/27/2022 | Q2 2022 | -$0.21 | -$0.23 | -0.02 | $0 | |
| 04/27/2022 | Q1 2022 | -$0.20 | -$0.21 | -0.01 | $0 | |
| 02/09/2022 | Q4 2021 | -$0.19 | -$0.16 | 0.03 | $0 | |
| 11/03/2021 | Q3 2021 | -$0.21 | -$0.17 | 0.04 | $0 | |
| 07/28/2021 | Q2 2021 | -$0.19 | -$0.20 | -0.01 | $0 | |
| 04/28/2021 | Q1 2021 | -$0.18 | -$0.19 | -0.01 | $0 | |
| 02/17/2021 | Q4 2020 | -$0.15 | -$0.15 | 0 | $0 | |
| 10/28/2020 | Q3 2020 | -$0.15 | -$0.13 | 0.02 | $0 | |
| 07/29/2020 | Q2 2020 | -$0.14 | -$0.13 | 0.01 | $0 | |
| 04/30/2020 | Q1 2020 | -$0.12 | -$0.13 | -0.01 | $0 | |
| 02/26/2020 | Q4 2019 | -$0.13 | -$0.10 | 0.03 | $0 |
Viking Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Viking Therapeutics, Inc.'s earnings date?
Viking Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based off last year's report dates.
-
Did Viking Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Viking Therapeutics, Inc. (:VKTX) reported $-0.22 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.24 by $0.02.
-
How can I listen to Viking Therapeutics, Inc.'s earnings conference call?
The conference call for Viking Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Viking Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Viking Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Viking Therapeutics, Inc. generate each year?
Viking Therapeutics, Inc. (:VKTX) has a recorded net income of $0. Viking Therapeutics, Inc. has generated $-0.91 earnings per share over the last four quarters.
-
What is Viking Therapeutics, Inc.'s price-to-earnings ratio?
Viking Therapeutics, Inc. (:VKTX) has a price-to-earnings ratio of -71.34 and price/earnings-to-growth ratio is -67.06.
